Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

988
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
988
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

861
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
861
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

312
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
312
Glaucoma: Overview01:25

Glaucoma: Overview

1.1K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.1K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

112
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
112

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Additional Considerations With DMEK Regrafts.

Cornea·2026
Same author

Response to Reframing the Risk in DMEK Regrafts: Host Environment Over Regraft Count.

Cornea·2026
Same author

p16-mediated G0/G1 cell cycle arrest leads to SASP and fibrosis in Fuchs endothelial corneal dystrophy.

Cell death & disease·2026
Same author

Chronic ER Stress Disrupts Mitochondrial-Associated ER Membrane Integrity in Corneal Endothelial Cells.

bioRxiv : the preprint server for biology·2026
Same author

Transcriptome analyses of human corneal endothelial cell lines derived from patients with Fuchs endothelial corneal dystrophy.

Scientific reports·2025
Same author

Permanent Senescence Via p16 Leads to Guttae Formation in an In Vitro Human Corneal Endothelial Cell Model.

Investigative ophthalmology & visual science·2025
Same journal

Visual arrestin-1: how did we learn what we know today about this protein?

Progress in retinal and eye research·2026
Same journal

Transcending genome-wide association studies to create useful multi-omic views of glaucoma.

Progress in retinal and eye research·2026
Same journal

Cutting-edge cross-linking biomaterials advancing ophthalmic therapeutics.

Progress in retinal and eye research·2026
Same journal

Scleral remodeling in myopia: mechanisms and therapeutic approaches.

Progress in retinal and eye research·2026
Same journal

Macular fibrosis secondary to neovascular age-related macular degeneration: from clinic to biology.

Progress in retinal and eye research·2026
Same journal

Stromal Transplantation and corneal-sparing techniques in ectatic diseases.

Progress in retinal and eye research·2026
See all related articles

Related Experiment Video

Updated: Dec 7, 2025

Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss
06:23

Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss

Published on: April 24, 2020

5.7K

Corneal endothelial dysfunction: Evolving understanding and treatment options.

Marianne O Price1, Jodhbir S Mehta2, Ula V Jurkunas3

  • 1Cornea Research Foundation of America, 9002 N. Meridian St., Suite 212, Indianapolis, IN, USA.

Progress in Retinal and Eye Research
|September 25, 2020
PubMed
Summary
This summary is machine-generated.

Corneal endothelial dysfunction causes vision loss, but advances in transplantation and new therapies like stem cells offer hope. Research is exploring alternatives to donor corneas to improve access to sight-saving treatments.

Keywords:
Bullous keratopathyCorneal endotheliumCultured human corneal endothelial cellsFuchs endothelial corneal dystrophyKeratoplasty

More Related Videos

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

Published on: August 20, 2016

8.2K
A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
12:36

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1

Published on: July 22, 2022

4.9K

Related Experiment Videos

Last Updated: Dec 7, 2025

Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss
06:23

Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss

Published on: April 24, 2020

5.7K
In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

Published on: August 20, 2016

8.2K
A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
12:36

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1

Published on: July 22, 2022

4.9K

Area of Science:

  • Ophthalmology
  • Regenerative Medicine
  • Biotechnology

Background:

  • The cornea's transparency relies on endothelial cell hydration.
  • Endothelial dysfunction leads to corneal edema and visual impairment.
  • Corneal transplantation is effective but limited by donor cornea scarcity.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for corneal endothelial dysfunction.
  • To highlight advancements in corneal transplantation and novel regenerative approaches.
  • To address the global shortage of donor corneas and improve patient access.

Main Methods:

  • Review of current clinical practices in endothelial keratoplasty.
  • Analysis of ongoing clinical trials for endothelial cell therapies.
  • Summary of pre-clinical research in stem cell therapy, gene therapy, and pharmacologic treatments.

Main Results:

  • Selective endothelial keratoplasty offers safe and effective visual rehabilitation.
  • Emerging therapies include autologous corneal regeneration, cultured endothelial cells, and stem cell treatments.
  • Pre-clinical studies show promise for induced pluripotent stem cells, gene therapy, and biologics.

Conclusions:

  • Advancements in corneal transplantation have improved outcomes and reduced complications.
  • Multiple innovative therapeutic avenues are being explored to overcome donor cornea limitations.
  • Future treatments aim to expand global access and personalize care for corneal endothelial dysfunction.